GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Henan Lingrui Pharmaceutical Co Ltd (SHSE:600285) » Definitions » YoY EPS Growth

Henan Lingrui Pharmaceutical Co (SHSE:600285) YoY EPS Growth : 9.77% (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Henan Lingrui Pharmaceutical Co YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Henan Lingrui Pharmaceutical Co's YoY EPS Growth for the quarter that ended in Sep. 2024 was 9.77%.

Henan Lingrui Pharmaceutical Co's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was ¥0.29.


Henan Lingrui Pharmaceutical Co YoY EPS Growth Historical Data

The historical data trend for Henan Lingrui Pharmaceutical Co's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Henan Lingrui Pharmaceutical Co YoY EPS Growth Chart

Henan Lingrui Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.27 11.91 11.34 28.37 22.47

Henan Lingrui Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.30 76.47 32.28 29.37 9.77

Henan Lingrui Pharmaceutical Co YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Henan Lingrui Pharmaceutical Co's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(1.003-0.819)/ | 0.819 |
=22.47 %

Henan Lingrui Pharmaceutical Co's YoY EPS Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EPS Growth (Q: Sep. 2024 )
=(Earnings per Share (Diluted) (Q: Sep. 2024 )-Earnings per Share (Diluted) (Q: Sep. 2023 )) / | Earnings per Share (Diluted) (Q: Sep. 2023 )) |
=(0.292-0.266)/ | 0.266 |
=9.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Henan Lingrui Pharmaceutical Co YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Henan Lingrui Pharmaceutical Co's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Henan Lingrui Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 59 Jiefang Chengguan Road, Xinxian, Xinyang, Henan, CHN, 465550
Henan Lingrui Pharmaceutical Co Ltd is a Chinese company engaged in the development, production, and distribution of pharmaceuticals. The Company's products include tablets, capsules, injections and other medicines.
Executives
Wu Xi Zhen Director
Li Jin Supervisors
Ye Qiang senior management
Chen Yan Directors, senior managers
Wu Hui Bin senior management
Yu Peng Director
Zhao Zhi Jun Director
Li Lei senior management
Feng Guo Xin Directors, senior managers
Pan Zi Run Director
Xiong Wei Zheng Director
Tang Wei Supervisors
Cheng Jian Jun Director
Zhang Jun Bing Director
Xia Hui senior management

Henan Lingrui Pharmaceutical Co Headlines

No Headlines